AMERICAN ONCOLOGIC HOSPIAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $26.6M
- Transactions
- 1,560
- Companies
- 40
- Average per transaction
- $17,039
Who reported the payments
| Merck | $5,541,587 |
| Novartis | $3,446,156 |
| E.r. Squibb & Sons, L.L.C. | $3,264,422 |
| Deciphera Pharmaceuticals Inc. | $2,570,704 |
| Seagen Inc. | $1,964,430 |
| Amgen | $1,557,670 |
| Genentech, Inc. | $1,329,355 |
| Pfizer | $1,238,616 |
| Janssen Research & Development, LLC | $816,126 |
| Otsuka Pharmaceutical Co., Ltd. | $713,293 |
| Fujifilm Corporation | $694,105 |
| Siemens Medical Solutions USA, Inc. | $567,318 |
| Incyte Corporation | $532,054 |
| Lilly USA, LLC | $372,828 |
| AstraZeneca | $297,202 |
| Blueprint Medicines Corporation | $297,100 |
| Agios Pharmaceuticals, Inc. | $236,505 |
| Tesaro, Inc. | $185,836 |
| GSK | $123,714 |
| F. Hoffmann-la Roche AG | $114,665 |
| Gilead | $114,620 |
| Innate Pharma, Inc | $100,798 |
| Sanofi US Services Inc. | $73,052 |
| Daiichi Sankyo Inc. | $67,762 |
| Fujifilm Healthcare Americas Corporation | $63,946 |
| Bayer | $50,018 |
| United Therapeutics Corporation | $40,843 |
| Astellas Pharma Global Development | $38,531 |
| Eli Lilly | $35,611 |
| Array Biopharma Inc | $32,583 |
| AbbVie | $24,316 |
| Angiodynamics, Inc. | $22,340 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,484 |
| Exelixis Inc. | $7,939 |
| Eisai Inc. | $5,000 |
| Boehringer Ingelheim | $5,000 |
| Kls-martin L.p. | $4,885 |
| Kyowa Kirin Pharmaceutical Development, Inc | $4,525 |
| Medical Device Business Services, Inc. | $2,500 |
| Johnson & Johnson | $2,500 |